Sugi Predict

Sugi Predict / Compounds / SCHEMBL873458

SCHEMBL873458

SCHEMBL873458

CC(C)(C)OC(=O)N1CCNC[C@@H]1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.54
▸ NR1H2 P55055 2/20 0.54
▸ NR1H3 Q13133 2/20 0.54
▸ CA1 P00915 2/20 0.54
▸ CA2 P00918 2/20 0.54
▸ CA4 P22748 2/20 0.54
▸ CA9 Q16790 2/20 0.54
▸ SLC6A2 P23975 3/20 0.50
▸ SLC6A4 P31645 3/20 0.50
▸ SLC6A3 Q01959 3/20 0.50
▸ DPP4 P27487 5/20 0.49
▸ REN P00797 2/20 0.48
▸ DPP7 Q9UHL4 2/20 0.48
▸ HDAC1 Q13547 1/20 0.47
▸ MITF O75030 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL873429 1.00 PARP1 (0.54) PARP1NR1H2NR1H3CA1CA2
SCHEMBL4309187 1.00 PARP1 (0.54) PARP1NR1H2NR1H3CA1CA2
SCHEMBL23540172 0.94 NR1H2 (0.50) PARP1NR1H2NR1H3CA1CA2
SCHEMBL874393 0.93 NR1H2 (0.52) PARP1NR1H2NR1H3CA1CA2
SCHEMBL877750 0.93 NR1H2 (0.52) PARP1NR1H2NR1H3CA1CA2
SCHEMBL877749 0.93 NR1H2 (0.52) PARP1NR1H2NR1H3CA1CA2
SCHEMBL8238773 0.90 PARP1 (0.54) PARP1NR1H2NR1H3CA1CA2
SCHEMBL15205855 0.89 PARP1 (0.56) PARP1NR1H2NR1H3CA1CA2
SCHEMBL2083157 0.89 NR1H2 (0.51) PARP1NR1H2NR1H3CA1CA2
SCHEMBL873617 0.89 NR1H2 (0.51) PARP1NR1H2NR1H3CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 — — CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 — — US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 — — EP claimed
US-12234225-B2 IL-17 ligands and uses thereof DICE ALPHA, INC. (US) 2025-02-25 — — US disclosed
CN-113874080-B IL-17A modulators and uses thereof 戴斯阿尔法公司 2024-09-27 — — CN disclosed
US-20230053746-A1 IL-17 LIGANDS AND USES THEREOF DICE MOLECULES SV, INC. 2023-02-23 — — US disclosed
US-11447468-B2 IL-17 ligands and uses thereof DICE ALPHA, INC. (US) 2022-09-20 — — US disclosed
CN-113874080-A IL-17A modulators and uses thereof 戴斯阿尔法公司 2021-12-31 — — CN disclosed
EP-3921038-A1 IL-17A MODULATORS AND USES THEREOF Dice Alpha, Inc. (US) 2021-12-15 — — EP disclosed
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-03-23 — — US disclosed
EP-2900666-B1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2020-11-04 — — EP disclosed
WO-2007100852-A1 THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS HELICON THERAPEUTICS, INC. (US) 2007-09-07 — — WO disclosed
US-20070203124-A1 Therapeutic Piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2007-08-30 — — US disclosed
WO-2006081230-A2 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER SCHERING CORPORATION (US) 2006-08-03 — — WO disclosed
US-5856326-A ANTITUMOR, ANTICANCER AGENTS MERCK & CO., INC. (US) 1999-01-05 — — US disclosed
CN-1195340-A Inhibitors of farnesyl-protein transferase MERCK & CO INC (US) 1998-10-07 — — CN disclosed
US-5736539-A ANITCARCINOGENIC AGENTS MERCK & CO., INC. (US) 1998-04-07 — — US disclosed
EP-0820445-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1998-01-28 — — EP disclosed
WO-1996030343-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-10-03 — — WO disclosed
WO-1995000497-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1995-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230053746-A1 IL-17 LIGANDS AND USES THEREOF IL17A, IL2, IL15 PARP1 3832/4885NR1H2 441/4885NR1H3 517/4885
US-20070203124-A1 Therapeutic Piperazines PDE4A, PDE4B, PDE12 PARP1 1492/4885NR1H2 744/4885NR1H3 1001/4885
US-11447468-B2 IL-17 ligands and uses thereof IL17A, IL2, IL15 PARP1 3832/4885NR1H2 441/4885NR1H3 517/4885
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C PRKX, PRKCQ, PRKACA PARP1 607/4885NR1H2 4208/4885NR1H3 4248/4885
US-12234225-B2 IL-17 ligands and uses thereof IL17A, IL2, IL15 PARP1 3832/4885NR1H2 441/4885NR1H3 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.